| pubmed-article:8421109 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8421109 | lifeskim:mentions | umls-concept:C0018213 | lld:lifeskim |
| pubmed-article:8421109 | lifeskim:mentions | umls-concept:C1456820 | lld:lifeskim |
| pubmed-article:8421109 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8421109 | pubmed:dateCreated | 1993-2-17 | lld:pubmed |
| pubmed-article:8421109 | pubmed:abstractText | In vitro tumor necrosis factor alpha (TNF alpha) exerts a synergistic action on HLA class II expression and a cytotoxic action in FRTL-5 cells. Therefore, a role for TNF alpha as a local mediator of cell destruction in thyroid autoimmunity has been postulated. To elucidate the in vivo significance of these and other in vitro findings for the pathophysiology of Graves' disease we investigated 11 thyroid glands of patients suffering from Graves' disease for TNF alpha. In situ hybridization was done with a TNF alpha probe synthesized with T7 polymerase on a 750-base pair EcoRI fragment of the coding region. Primers at positions 152 and 854 in the TNF alpha copy DNA sequence were used for reverse polymerase chain reaction (PCR) amplification of TNF alpha in 5 patients. Immunohistological staining for TNF alpha was done with a mouse monoclonal antibody. We could not detect any TNF alpha and TNF alpha messenger RNA in thyroid tissue of 11 patients suffering mostly from relapsing Graves' disease by immunohistology and in situ hybridization as well as reverse PCR, respectively. A faint signal could be detected by reverse PCR in control thyroid tissue from a patient with recurrent goiter. This lack of intrathyroidal TNF alpha in relapsing Graves' disease is in accordance with a lack of increased TNF alpha production by T cell clones isolated from Graves' disease thyroid glands and contrasts with previous in vitro results. Since protective TNF actions have been demonstrated in other autoimmune diseases it could therefore be envisaged that the lack of intrathyroidal TNF alpha may be associated with the relapse of Graves' disease in our patients. | lld:pubmed |
| pubmed-article:8421109 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8421109 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8421109 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8421109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8421109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8421109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8421109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8421109 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8421109 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:8421109 | pubmed:issn | 0021-972X | lld:pubmed |
| pubmed-article:8421109 | pubmed:author | pubmed-author:UsadelK HKH | lld:pubmed |
| pubmed-article:8421109 | pubmed:author | pubmed-author:ESODAE C JEC | lld:pubmed |
| pubmed-article:8421109 | pubmed:author | pubmed-author:FEYCC | lld:pubmed |
| pubmed-article:8421109 | pubmed:author | pubmed-author:PaschkeRR | lld:pubmed |
| pubmed-article:8421109 | pubmed:author | pubmed-author:KistAA | lld:pubmed |
| pubmed-article:8421109 | pubmed:author | pubmed-author:JänickeRR | lld:pubmed |
| pubmed-article:8421109 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8421109 | pubmed:volume | 76 | lld:pubmed |
| pubmed-article:8421109 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8421109 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8421109 | pubmed:pagination | 97-102 | lld:pubmed |
| pubmed-article:8421109 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8421109 | pubmed:meshHeading | pubmed-meshheading:8421109-... | lld:pubmed |
| pubmed-article:8421109 | pubmed:meshHeading | pubmed-meshheading:8421109-... | lld:pubmed |
| pubmed-article:8421109 | pubmed:meshHeading | pubmed-meshheading:8421109-... | lld:pubmed |
| pubmed-article:8421109 | pubmed:meshHeading | pubmed-meshheading:8421109-... | lld:pubmed |
| pubmed-article:8421109 | pubmed:meshHeading | pubmed-meshheading:8421109-... | lld:pubmed |
| pubmed-article:8421109 | pubmed:meshHeading | pubmed-meshheading:8421109-... | lld:pubmed |
| pubmed-article:8421109 | pubmed:meshHeading | pubmed-meshheading:8421109-... | lld:pubmed |
| pubmed-article:8421109 | pubmed:meshHeading | pubmed-meshheading:8421109-... | lld:pubmed |
| pubmed-article:8421109 | pubmed:meshHeading | pubmed-meshheading:8421109-... | lld:pubmed |
| pubmed-article:8421109 | pubmed:meshHeading | pubmed-meshheading:8421109-... | lld:pubmed |
| pubmed-article:8421109 | pubmed:meshHeading | pubmed-meshheading:8421109-... | lld:pubmed |
| pubmed-article:8421109 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8421109 | pubmed:articleTitle | Lack of intrathyroidal tumor necrosis factor alpha in Graves' disease. | lld:pubmed |
| pubmed-article:8421109 | pubmed:affiliation | Service de Génétique, Faculté de Medecine, Université Libre de Bruxelles, Belgique. | lld:pubmed |
| pubmed-article:8421109 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8421109 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
